Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes.

Printer-friendly versionPrinter-friendly versionPDF versionPDF version
TitleDifferential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes.
Publication TypeJournal Article
Year of Publication2008
AuthorsGarnacho, C, Albelda, SM, Muzykantov, VR, Muro, S
JournalJ Control Release
Volume130
Issue3
Pagination226-33
Date Published2008 Sep 24
ISSN1873-4995
KeywordsAntibodies, Monoclonal, Antigen-Antibody Reactions, Antigens, CD31, Binding Sites, Antibody, Biotin, Cells, Cultured, Drug Delivery Systems, Endocytosis, Endosomes, Endothelial Cells, Epitopes, Humans, Lysosomes, Microspheres, Nanoparticles, Particle Size, Polystyrenes, Streptavidin
Abstract

Coupling drug carriers to antibodies for targeting endothelial cells (ECs) may improve treatment of vascular and pulmonary diseases. Selecting antibodies that deliver carriers to the cell surface or intracellularly may further optimize specificity of interventions. We studied antibody-directed targeting of nanocarriers to platelet-endothelial cell adhesion molecule (PECAM)-1, an endothelial glycoprotein containing 6 Ig-like extracellular domains. PECAM-1 antibodies bind to ECs without internalization, but ECs internalize by endocytosis nanocarriers carrying multiple copies of anti-PECAM (anti-PECAM/NCs). To determine whether binding and intracellular transport of anti-PECAM/NCs depend on the epitope engaged, we targeted five PECAM-1 epitopes: mAb35, mAb37 and mAb62 (membrane-distal Ig domain 1), mAbGi34 (Ig domains 2/3), and mAb4G6 (membrane-proximal Ig domain 6). The antibodies bound to ECs regardless of the epitope proximity to the plasmalemma, whereas 130 nm diameter nanocarriers only targeted effectively distal domains (mAb4G6/NCs did not bind to ECs). ECs internalized mAb35, mAb62, and mAbGi34 carriers regardless of their size (0.13 to 5 microm diameter), yet they did not internalize mAb37/NCs. After internalization, mAb62/NCs trafficked to lysosomes within 2-3 h, whereas mAb35/NCs had prolonged residence in pre-lysosomal vesicles. Therefore, endothelial binding, endocytosis, and intracellular transport of anti-PECAM/NCs are epitope-specific. This paradigm will guide the design of endothelial drug delivery systems providing specific cellular localizations.

DOI10.1016/j.jconrel.2008.06.007
Alternate JournalJ Control Release
PubMed ID18606202
PubMed Central IDPMC2615664
Grant ListHL/GM71175 / GM / NIGMS NIH HHS / United States
P30 DK47757 / DK / NIDDK NIH HHS / United States
R01 HL071175-04 / HL / NHLBI NIH HHS / United States
R01 HL087036-04 / HL / NHLBI NIH HHS / United States
R01 HL087036-05 / HL / NHLBI NIH HHS / United States
R21 HL085533-02 / HL / NHLBI NIH HHS / United States
R21 HL85533 / HL / NHLBI NIH HHS / United States